Shares of biopharma company Alexion (ALXN) opened up 7% when market started today after it reported a rise in Q1 2018 earnings and revenue, and lifted the guidance for the year. Along with this, the company also reported a positive top line results for its Phase 3 study.
The company that specializes in manufacturing drugs for rare disorder reported a 7% increase in its revenue to $930.9 million. Earnings per share rose 48% to $1.11 and excluding items, the company’s earnings per share rose 22% during the quarter.
Net product sales of the key drug Soliris, which accounts for a bulk of the company’s revenue and is used to treat serious genetic-based blood condition, grew 2% during the quarter to $800.1 million.
Alexion has been working aggressively on rebuilding its pipeline. This is one of the reasons why it recently acquired Wilson Therapeutics based in Sweden. This deal, valued at $855 million, gives Alexion a greater control over the Wilson’s rare disease drug WTX101. Also, this new drug will reduce the company’s complete dependence on Soliris for generating revenue. The transaction is expected to close during the second quarter of this year.
The drugmaker also reported positive topline results for its Phase 3 study that is again used to treat a rare blood disorder called paroxysmal nocturnal hemoglobinuria (PNH).
The company also raised its guidance for revenue and adjusted EPS for the full year. Alexion now expects its revenue to be in the range of about $3.93 to 3.99 billion, up from the previous estimate of $3.85 to $3.95 billion and adjusted EPS to be about $6.75 to $6.90, up from the prior estimate of $6.60 to $6.80.
Today, apart from Alexion, two other drugmakers reported their results before the market opened. While AbbVie (ABBV) reported strong results and trades in the positive territory, Bristol-Myers Squibb (BMY) shares were down 1% in the morning session. Vertex Pharmaceuticals (VRTX) will announce its quarterly results after the market closes today.
Most Popular
Microsoft (MSFT) reports higher revenue and profit for Q3 2024
Microsoft Corp. (NASDAQ: MSFT) on Thursday said its third-quarter 2024 earnings increased year-over-year, reflecting strong performance by the tech giant’s main operating segments. Third-quarter revenues came in at $61.86 billion,
GOOG, GOOGL Earnings: All you need to know about Alphabet’s Q1 2024 earnings results
Alphabet Inc. (NASDAQ: GOOG, GOOGL) reported its first quarter 2024 earnings results today. Revenues increased 15% year-over-year to $80.5 billion. Revenue growth was 16% in constant currency. Net income was
MRK Earnings: Merck Q1 2024 profit jumps on 9% revenue growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the first quarter of 2024, aided by an increase in revenues. First-quarter worldwide sales